0
Nov 15 (Reuters) – Novo Nordisk A/S: * NOVO'S CAGRISEMA WAS ASSOCIATED WITH 25% MEAN WEIGHT LOSS AMONG EARLY RESPONDERS IN A POST HOC ANALYSIS OF REDEFINE 1 PRESENTED AT OBESITYWEEK® 2026 * NOVO:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
